Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease

Edwin M. Spithoven, Anneke Kramer, Esther Meijer, Bjarne Orskov, Christoph Wanner, Fergus Caskey, Frederic Collart, Patrik Finne, Damian G. Fogarty, Jaap W. Groothoff, Andries Hoitsma, Marie Béatrice Nogier, Maurizio Postorino, Pietro Ravani, Oscar Zurriaga, Kitty J. Jager, Ron T. Gansevoort, N. Aresté, M. Arias, C. CouchoudK. Budde, D. Chauveau, O. Devuyst, T. Ecder, K. U. Eckardt, R. T. Gansevoort, A. Köttgen, A. C. Ong, K. Petzold, Y. Pirson, G. Remuzzi, R. Torra, R. N. Sandford, A. L. Serra, V. Tesar, G. Walz, R. P. Wüthrich, C. Antignac, R. Bindels, D. Chauveau, O. Devuyst, F. Emma, R. T. Gansevoort, P. H. Maxwell, A. C. Ong, G. Remuzzi, P. Ronco, F. Schaefer

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to postpone the need for renal replacement therapy (RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with inconclusive results. To help resolve this we determined changes in RRT incidence rates as an indicator for increasing effective renoprotection over time in ADPKD. We analyzed data from the European Renal Association-European Dialyses and Transplant Association Registry on 315,444 patients starting RRT in 12 European countries between 1991 and 2010, grouped into four 5-year periods. Of them, 20,596 were due to ADPKD. Between the first and last period the mean age at onset of RRT increased from 56.6 to 58.0 years. The age- and gender-adjusted incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 8.3 per million population. No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased. Among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and ADPKD. Thus, the increased age at onset of RRT is most likely due to an increased access for elderly ADPKD patients or lower competing risk prior to the start of RRT rather than the consequence of effective emerging renoprotective treatments for ADPKD.

Original languageEnglish
Pages (from-to)1244-1252
Number of pages9
JournalKidney International
Volume86
Issue number6
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Autosomal Dominant Polycystic Kidney
Renal Replacement Therapy
Chronic Renal Insufficiency
Edetic Acid
Registries
Polycystic Kidney Diseases
Therapeutics
Incidence
Age of Onset
Kidney Diseases
Renal Insufficiency
Transplants

Keywords

  • ADPKD
  • Epidemiology
  • Renoprotective therapy

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. / Spithoven, Edwin M.; Kramer, Anneke; Meijer, Esther; Orskov, Bjarne; Wanner, Christoph; Caskey, Fergus; Collart, Frederic; Finne, Patrik; Fogarty, Damian G.; Groothoff, Jaap W.; Hoitsma, Andries; Nogier, Marie Béatrice; Postorino, Maurizio; Ravani, Pietro; Zurriaga, Oscar; Jager, Kitty J.; Gansevoort, Ron T.; Aresté, N.; Arias, M.; Couchoud, C.; Budde, K.; Chauveau, D.; Devuyst, O.; Ecder, T.; Eckardt, K. U.; Gansevoort, R. T.; Köttgen, A.; Ong, A. C.; Petzold, K.; Pirson, Y.; Remuzzi, G.; Torra, R.; Sandford, R. N.; Serra, A. L.; Tesar, V.; Walz, G.; Wüthrich, R. P.; Antignac, C.; Bindels, R.; Chauveau, D.; Devuyst, O.; Emma, F.; Gansevoort, R. T.; Maxwell, P. H.; Ong, A. C.; Remuzzi, G.; Ronco, P.; Schaefer, F.

In: Kidney International, Vol. 86, No. 6, 01.01.2014, p. 1244-1252.

Research output: Contribution to journalArticle

Spithoven, EM, Kramer, A, Meijer, E, Orskov, B, Wanner, C, Caskey, F, Collart, F, Finne, P, Fogarty, DG, Groothoff, JW, Hoitsma, A, Nogier, MB, Postorino, M, Ravani, P, Zurriaga, O, Jager, KJ, Gansevoort, RT, Aresté, N, Arias, M, Couchoud, C, Budde, K, Chauveau, D, Devuyst, O, Ecder, T, Eckardt, KU, Gansevoort, RT, Köttgen, A, Ong, AC, Petzold, K, Pirson, Y, Remuzzi, G, Torra, R, Sandford, RN, Serra, AL, Tesar, V, Walz, G, Wüthrich, RP, Antignac, C, Bindels, R, Chauveau, D, Devuyst, O, Emma, F, Gansevoort, RT, Maxwell, PH, Ong, AC, Remuzzi, G, Ronco, P & Schaefer, F 2014, 'Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease', Kidney International, vol. 86, no. 6, pp. 1244-1252. https://doi.org/10.1038/ki.2014.120
Spithoven, Edwin M. ; Kramer, Anneke ; Meijer, Esther ; Orskov, Bjarne ; Wanner, Christoph ; Caskey, Fergus ; Collart, Frederic ; Finne, Patrik ; Fogarty, Damian G. ; Groothoff, Jaap W. ; Hoitsma, Andries ; Nogier, Marie Béatrice ; Postorino, Maurizio ; Ravani, Pietro ; Zurriaga, Oscar ; Jager, Kitty J. ; Gansevoort, Ron T. ; Aresté, N. ; Arias, M. ; Couchoud, C. ; Budde, K. ; Chauveau, D. ; Devuyst, O. ; Ecder, T. ; Eckardt, K. U. ; Gansevoort, R. T. ; Köttgen, A. ; Ong, A. C. ; Petzold, K. ; Pirson, Y. ; Remuzzi, G. ; Torra, R. ; Sandford, R. N. ; Serra, A. L. ; Tesar, V. ; Walz, G. ; Wüthrich, R. P. ; Antignac, C. ; Bindels, R. ; Chauveau, D. ; Devuyst, O. ; Emma, F. ; Gansevoort, R. T. ; Maxwell, P. H. ; Ong, A. C. ; Remuzzi, G. ; Ronco, P. ; Schaefer, F. / Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. In: Kidney International. 2014 ; Vol. 86, No. 6. pp. 1244-1252.
@article{24608b85eec2416bbdf5d85c97a4a8ad,
title = "Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease",
abstract = "Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to postpone the need for renal replacement therapy (RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with inconclusive results. To help resolve this we determined changes in RRT incidence rates as an indicator for increasing effective renoprotection over time in ADPKD. We analyzed data from the European Renal Association-European Dialyses and Transplant Association Registry on 315,444 patients starting RRT in 12 European countries between 1991 and 2010, grouped into four 5-year periods. Of them, 20,596 were due to ADPKD. Between the first and last period the mean age at onset of RRT increased from 56.6 to 58.0 years. The age- and gender-adjusted incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 8.3 per million population. No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased. Among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and ADPKD. Thus, the increased age at onset of RRT is most likely due to an increased access for elderly ADPKD patients or lower competing risk prior to the start of RRT rather than the consequence of effective emerging renoprotective treatments for ADPKD.",
keywords = "ADPKD, Epidemiology, Renoprotective therapy",
author = "Spithoven, {Edwin M.} and Anneke Kramer and Esther Meijer and Bjarne Orskov and Christoph Wanner and Fergus Caskey and Frederic Collart and Patrik Finne and Fogarty, {Damian G.} and Groothoff, {Jaap W.} and Andries Hoitsma and Nogier, {Marie B{\'e}atrice} and Maurizio Postorino and Pietro Ravani and Oscar Zurriaga and Jager, {Kitty J.} and Gansevoort, {Ron T.} and N. Arest{\'e} and M. Arias and C. Couchoud and K. Budde and D. Chauveau and O. Devuyst and T. Ecder and Eckardt, {K. U.} and Gansevoort, {R. T.} and A. K{\"o}ttgen and Ong, {A. C.} and K. Petzold and Y. Pirson and G. Remuzzi and R. Torra and Sandford, {R. N.} and Serra, {A. L.} and V. Tesar and G. Walz and W{\"u}thrich, {R. P.} and C. Antignac and R. Bindels and D. Chauveau and O. Devuyst and F. Emma and Gansevoort, {R. T.} and Maxwell, {P. H.} and Ong, {A. C.} and G. Remuzzi and P. Ronco and F. Schaefer",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/ki.2014.120",
language = "English",
volume = "86",
pages = "1244--1252",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease

AU - Spithoven, Edwin M.

AU - Kramer, Anneke

AU - Meijer, Esther

AU - Orskov, Bjarne

AU - Wanner, Christoph

AU - Caskey, Fergus

AU - Collart, Frederic

AU - Finne, Patrik

AU - Fogarty, Damian G.

AU - Groothoff, Jaap W.

AU - Hoitsma, Andries

AU - Nogier, Marie Béatrice

AU - Postorino, Maurizio

AU - Ravani, Pietro

AU - Zurriaga, Oscar

AU - Jager, Kitty J.

AU - Gansevoort, Ron T.

AU - Aresté, N.

AU - Arias, M.

AU - Couchoud, C.

AU - Budde, K.

AU - Chauveau, D.

AU - Devuyst, O.

AU - Ecder, T.

AU - Eckardt, K. U.

AU - Gansevoort, R. T.

AU - Köttgen, A.

AU - Ong, A. C.

AU - Petzold, K.

AU - Pirson, Y.

AU - Remuzzi, G.

AU - Torra, R.

AU - Sandford, R. N.

AU - Serra, A. L.

AU - Tesar, V.

AU - Walz, G.

AU - Wüthrich, R. P.

AU - Antignac, C.

AU - Bindels, R.

AU - Chauveau, D.

AU - Devuyst, O.

AU - Emma, F.

AU - Gansevoort, R. T.

AU - Maxwell, P. H.

AU - Ong, A. C.

AU - Remuzzi, G.

AU - Ronco, P.

AU - Schaefer, F.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to postpone the need for renal replacement therapy (RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with inconclusive results. To help resolve this we determined changes in RRT incidence rates as an indicator for increasing effective renoprotection over time in ADPKD. We analyzed data from the European Renal Association-European Dialyses and Transplant Association Registry on 315,444 patients starting RRT in 12 European countries between 1991 and 2010, grouped into four 5-year periods. Of them, 20,596 were due to ADPKD. Between the first and last period the mean age at onset of RRT increased from 56.6 to 58.0 years. The age- and gender-adjusted incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 8.3 per million population. No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased. Among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and ADPKD. Thus, the increased age at onset of RRT is most likely due to an increased access for elderly ADPKD patients or lower competing risk prior to the start of RRT rather than the consequence of effective emerging renoprotective treatments for ADPKD.

AB - Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to postpone the need for renal replacement therapy (RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with inconclusive results. To help resolve this we determined changes in RRT incidence rates as an indicator for increasing effective renoprotection over time in ADPKD. We analyzed data from the European Renal Association-European Dialyses and Transplant Association Registry on 315,444 patients starting RRT in 12 European countries between 1991 and 2010, grouped into four 5-year periods. Of them, 20,596 were due to ADPKD. Between the first and last period the mean age at onset of RRT increased from 56.6 to 58.0 years. The age- and gender-adjusted incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 8.3 per million population. No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased. Among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and ADPKD. Thus, the increased age at onset of RRT is most likely due to an increased access for elderly ADPKD patients or lower competing risk prior to the start of RRT rather than the consequence of effective emerging renoprotective treatments for ADPKD.

KW - ADPKD

KW - Epidemiology

KW - Renoprotective therapy

UR - http://www.scopus.com/inward/record.url?scp=84912004429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912004429&partnerID=8YFLogxK

U2 - 10.1038/ki.2014.120

DO - 10.1038/ki.2014.120

M3 - Article

C2 - 24827775

AN - SCOPUS:84912004429

VL - 86

SP - 1244

EP - 1252

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -